Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New Yor...
November 07 2017 - 11:15AM
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report
on the two data presentations which were held on Fexapotide
Triflutate studies at the Annual Meeting of the American Urological
Association, New York Section in Havana, November 6. The
abstract from the presentation is available at info@nymox.com.
The Podium presentation was given by Dr. Ivan
Grunberger MD FACS, Professor of Clinical Urology, Weill Cornell
Medical College and Chief of Urology, NYP Brooklyn Methodist
Hospital. The paper was entitled “Prospective Randomized Double
Blind Phase 3 Long-Term Results of U.S. Studies of Fexapotide
Triflutate For BPH.” Co-authors of the Podium presentation were
Ronald Tutrone MD FACS of Baltimore MD, Mitchell Efros MD FACS of
Garden City NY, Mohammed Bidair MD of San Diego CA, James
Bailen MD FACS of Louisville KY, Franklin Gaylis MD FACS of San
Diego CA, Barton Wachs MD of Long Beach CA, Richard Levin MD FACS
of Baltimore MD, Susan Kalota MD of Tucson AZ, Sheldon Freedman MD
FACS of Las Vegas NV, Barry Shepard MD FACS of Garden City NY, Jed
Kaminetsky MD FACS of New York NY, Steven Gange MD FACS of Salt
Lake City UT and Dr. Grunberger of Brooklyn NY.
Dr. Grunberger said, “Our presentation of the
long-term data was very well received by the participants at the NY
Section AUA meeting today. I received a lot of positive feedback
following the presentation, and a great deal of interest in the use
of Fexapotide Triflutate for patients with BPH once available.”
The symposium “Fexapotide Triflutate: First in
Class Injectable for BPH” was chaired by Dr. Tutrone. The other
panel members at the Symposium were Dr. Jeffrey Snyder MD FACS of
Denver CO, Dr. Kenneth Goldberg MD FACS of Carrollton TX, and Dr.
Grunberger of Brooklyn NY.
Dr. Tutrone said, "I see Fexapotide Triflutate
as a first line therapy for men suffering from BPH. It is a quick,
painless and safe in-office procedure that takes minutes to do, and
does not require a catheter. Its long term efficacy is better than
oral medications, and there are no sexual side effects."
At the Symposium detailed clinical data on the
Phase 3 clinical trials that have been completed for Fexapotide and
that have shown excellent safety and efficacy for the treatment of
BPH was presented. The main presentation was followed by a panel
discussion and by an interactive question and answer session with
the specialist doctors in attendance.
Dr. Snyder said, “I am most encouraged by the
clinical trial data presented at the NY Section of the AUA meeting
in Havana, Cuba today. This compound is a novel and effective
approach to caring for men with symptoms of an enlarged prostate.
It is my opinion that the drug will enhance the therapeutic
armamentarium of urologists worldwide and maintain our expertise in
the treatment of prostate disease. ”
Fexapotide has been filed for approval in Europe
and the filing was accepted for review in September 2017. Nymox's
lead drug Fexapotide has been in development for over 10 years and
has been tested by expert clinical trial investigative teams in
over 70 distinguished clinical trial centers throughout the US, and
has been found after 7 years of prospective placebo controlled
double blind studies of treatment of 995 U.S. men with prostate
enlargement to not only show clinically meaningful and durable
relief of BPH symptoms, but also to show a major reduction in the
incidence of prostate cancer, compared to placebo and compared to
the known and expected normal incidence of the disease. The same
clinical program has also shown in a long-term blinded placebo
crossover group study an 82-95% reduction in the number of these
patients who required surgery after they received crossover
Fexapotide in the trial, as compared to patients who did not
receive Fexapotide but instead received crossover conventional
approved BPH treatments (p<.0001).
For more information please
contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2016, and its Quarterly Reports.
For Further Information
Contact:Paul AverbackNymox Pharmaceutical
Corporation1-800-93NYMOXwww.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Sep 2023 to Sep 2024